Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Recent News

Relapsed AML in Children and Hematopoietic Cell Transplantation
Predicting Low-Risk Febrile Neutropenia in Chemotherapy-Treated Patients With AML
Suicide Risk Factors for Patients With AML and Other Leukemias
Anti–TIM-3 Monoclonal Antibody Under Study in AML
Rare Occurrence of Secondary CML After AML: Case Study
Novel Treatment Under Study in Transplantation-Eligible Patients With AML
Early Results With Eftozanermin Alfa Plus Venetoclax in AML
How Does Minimal Residual Disease Impact Clinical Outcomes in Acute Leukemias?
Venetoclax Combination Therapy for Acute Myeloid Leukemia Approved by FDA
Potential of IDH1 Inhibitors in AML Prior to Hematopoietic Cell Transplantation
SIERRA Trial Update on Novel Conditioning Regimen for Older Patients With AML
Pediatric AML: Combination Therapy With Venetoclax and Azacitidine
SOHO 2020: GI Side Effects for Patients With AML Treated With CC-486
SOHO 2020: Survival Update From BRIGHT Trial of Glasdegib-Based Therapy for AML
Long-Term Psychosocial and Neurocognitive Impact of Childhood AML
SOHO 2020: Elevated LDH Levels and Overall Survival in AML
Clinical Implications of Condensing HDAC Regimen in Treatment of AML
NPM1‐Mutant AML and COVID-19: Modified Protocols for Monitoring Treatment Response
Stem Cell Transplantation and AML: WT1 Expression and Outcomes
Azacitidine Tablets Approved by FDA for Patients With AML in First Remission
Selinexor in Refractory Oligoblastic AML: Phase II Trial Findings
AML and COVID-19: Treatment Lessons Learned
Glasdegib After Transplantation in Patients With AML at High Risk for Relapse
Does Treatment Delay Affect Outcomes in AML?
Personalized Immunotherapy for Resistant AML
Antimetabolite Aspacytarabine Receives Fast Track Designation for AML Treatment
New ASH Guidelines Focus on Managing AML in Older Adults
Use of Anthracyclines and Stem Cell Transplantation in AML: Outcomes by Age
Primary Antifungal Prophylaxis in Patients Treated for Acute Myeloid Leukemia
Factors Predictive of Response to Venetoclax Treatment in AML
Third-Generation BCR-ABL Inhibitor Under Study in AML
AACR COVID: Clinical Experience in Treating Pediatric Patients With AML and Coronavirus
Pexidartinib for Relapsed or Refractory FLT3-ITD–Mutant AML
EHA25: Ponatinib Plus Azacitidine for FLT3-Mutated AML
Occupational Exposure to Pesticides and AML Risk
EHA25: Early Results With Alvocidib Followed by Chemotherapy for Newly Diagnosed AML
EHA25 Virtual: 6-Month VIALE-C Update on Venetoclax With Low-Dose Cytarabine in AML
Early Blood Cell Counts and Survival After Treatment of Newly Diagnosed AML
EHA25 Virtual: 5-Year Follow-up on Novel Dual-Drug Formulation in AML
Using Patient-Reported Data to Predict Survival in AML
EHA25 Virtual: FLT3 Inhibitor Plus Chemotherapy for Younger Patients With AML
ASCO20: 1-Year ADMIRAL Trial Update on Gilteritinib in Resistant AML
AACR II: Race-Based Survival Differences in Patients With AML Living in Texas
EHA25 Virtual: Venetoclax Plus Low-Dose Cytarabine for Older Adults With AML
First-in-Class Immunotherapy With Azacitidine Under Study in AML
FDA Approves Gemtuzumab Ozogamicin for Pediatric CD33-Positive AML
EHA25 Virtual: Azacitidine Versus Fludarabine Plus Cytarabine in Elderly Patients With AML
EHA25 Virtual: Venetoclax Plus Azacitidine in Older Patients With AML Who Are Ineligible for Intensive Therapy
ASCO20: Ivosidenib and Venetoclax in Treatment of IDH1-Mutated AML
ASCO20: Escalated Dosing Schedule of CC-486 in Patients With AML in First Relapse
ASCO20: Enasidenib Plus Azacitidine in Newly Diagnosed Mutant-IDH2 AML
ASCO20: Is Palliative Care of Benefit in Patients With High-Risk AML?
ASCO20: Adding Venetoclax to Cytarabine in Older Patients With AML


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.